Fax: (202) 444-9429.
Targeted therapy in prostate cancer—Are we our own worst enemy?†
Article first published online: 8 SEP 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 9, pages 2376–2378, 1 November 2008
How to Cite
Dawson, N. A. (2008), Targeted therapy in prostate cancer—Are we our own worst enemy?. Cancer, 113: 2376–2378. doi: 10.1002/cncr.23865
See referenced original article on pages 2478–87, this issue.
- Issue published online: 17 OCT 2008
- Article first published online: 8 SEP 2008
- Manuscript Accepted: 18 JUN 2008
- Manuscript Received: 16 JUN 2008
- 6Impact of the specific endothelial A receptor antagonist ZD4054 on overall survival and bone metastases in patients with hormone-resistant prostate cancer: results of a phase II trial [abstract]. Presented at the ASCO 2008 Genitourinary Cancers Symposium, San Francisco, California, February 14-16, 2008. Abstract 7., , , et al.
- 7Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone [abstract]. Presented at the American Society for Bone and Mineral Research 27th Annual Meeting, Nashville, Tennessee, September 23-27, 2005. Abstract 1213a., , , et al.